# Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer

> **NCT07534033** · PHASE2 · RECRUITING · sponsor: **Zhujiang Hospital** · enrollment: 46 (estimated)

## Conditions studied

- NSCLC Diagnosed by Histology or Cytology
- A Multidisciplinary Team Assessment Determined That the Patient Was a Suitable Candidate for Radical Surgical Resection
- Overall Lung Function is Adequate for the Planned Lung Resection
- AJCC is Classified as IB-IIIC

## Interventions

- **DRUG:** Probiotics combined with neoadjuvant chemoimmunotherapy

## Key facts

- **NCT ID:** NCT07534033
- **Lead sponsor:** Zhujiang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-06
- **Primary completion:** 2026-12-23
- **Final completion:** 2027-12-23
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07534033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07534033, "Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07534033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*